Pneumonia, pneumonitis, or progressive disease during immunotherapy in lung cancer?
Registration for this session is additional to the congress registration fee and is €122 on site, €110 standard.
Aims : Access educational materials here
Immunotherapy in advanced NSCLC is advancing to a new standard of care and is currently being administered more frequently and to a broader patient population. The aim of this session is to present three different cases of lung cancer lesions that were treated with immunotherapy and exhibited radiological progression that was due to pneumonia, pneumonitis, or tumour disease progression.
Target audience :
Allergologist, Clinician, Emergency medicine doctor, Fellow, General practitioner, Immunologist, Intensivist/critical care physician, Junior member, Microbiologist, Nurse, Oncologist, Pathologist, Patient, Pharmaceutical industry representative, Pulmonologist, Radiologist, Researcher, Resident, Respiratory physician, Respiratory therapist, Scientist, Student, Thoracic endoscopist, Thoracic surgeon, Trainee